FDA finalizes guidance on prescription drug apps

On Oct. 20, 2026, the U.S. Food and Drug Administration finalized guidance that clarifies how drug manufacturers must label and submit content that appears in companion apps for prescription medicines. The guidance aims to make the information that patients see in apps part of the drug’s official labeling.

How the guidance differs for app types

The guidance separates companion software into two main groups. Apps that are physically linked to a medical device, such as inhaler‑connected software, are treated as part of the drug’s prescribing information. Standalone apps that track symptoms, give dose reminders, or offer health coaching are only required to be listed in the label if the manufacturer shows they are essential for safe and effective use or provide a meaningful clinical benefit. Otherwise, the content is treated as promotional material.

To help manufacturers decide how to label an app, the guidance includes a decision tree and sample language for device‑connected and standalone software. It also recommends that if a device‑connected app has not demonstrated a clinical benefit, the label should note that. The new rules do not require companies to resubmit app content that has not changed.

The guidance does not serve as an approval or endorsement of any particular app. It covers software that is distributed by or on behalf of a drugmaker, leaving independent free apps outside its scope. The policy also clarifies that the information an app shows is subject to the same FDA oversight as the drug’s labeling.

The agency said the guidance will reduce regulatory uncertainty for both drug makers and technology developers while keeping safety and effectiveness standards high. By clarifying how companion apps are regulated, the FDA hopes to encourage responsible digital health innovation that supports patients’ daily medication use.